HC Wainwright Analysts Lower Earnings Estimates for NBIX

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at HC Wainwright dropped their Q4 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a research report issued to clients and investors on Friday, February 21st. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of $1.06 for the quarter, down from their prior estimate of $1.20. HC Wainwright has a “Buy” rating and a $185.00 price target on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences’ FY2026 earnings at $4.43 EPS, FY2027 earnings at $7.33 EPS and FY2029 earnings at $14.69 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%.

NBIX has been the topic of a number of other research reports. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Wedbush dropped their target price on Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. UBS Group lifted their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Bank of America dropped their target price on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 18th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $166.90.

Neurocrine Biosciences Trading Up 3.9 %

Shares of Neurocrine Biosciences stock opened at $120.69 on Monday. Neurocrine Biosciences has a twelve month low of $110.95 and a twelve month high of $157.98. The stock has a market capitalization of $12.03 billion, a P/E ratio of 36.68, a PEG ratio of 0.77 and a beta of 0.33. The business’s fifty day moving average price is $136.63 and its 200 day moving average price is $129.31.

Neurocrine Biosciences declared that its board has initiated a stock buyback plan on Friday, February 21st that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 4.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Julie Cooke sold 1,740 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $152.89, for a total value of $266,028.60. Following the completion of the sale, the insider now directly owns 18,202 shares in the company, valued at $2,782,903.78. This represents a 8.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kevin Charles Gorman sold 5,844 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total value of $681,936.36. Following the completion of the sale, the director now owns 521,618 shares of the company’s stock, valued at $60,867,604.42. This trade represents a 1.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 236,600 shares of company stock worth $34,348,261 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Golden State Wealth Management LLC acquired a new stake in Neurocrine Biosciences in the fourth quarter worth approximately $25,000. Huntington National Bank lifted its position in Neurocrine Biosciences by 73.5% in the fourth quarter. Huntington National Bank now owns 229 shares of the company’s stock worth $31,000 after purchasing an additional 97 shares during the period. Brooklyn Investment Group lifted its position in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after purchasing an additional 115 shares during the period. GeoWealth Management LLC lifted its position in Neurocrine Biosciences by 65.4% in the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock worth $35,000 after purchasing an additional 102 shares during the period. Finally, Blue Trust Inc. lifted its position in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.